Kalegowda Shivashankar

Emerging genomic, epigenomic, and preclinical studies have implicated epigenetic dysregulation as a primary hallmark of ASD. Targeting epigenetic enzymes may hold the key to restore gene expression homeostasis, leading to the normalization of synaptic function and the mitigation of behavioral abnormalities in ASD. Epigenetic drugs are promising for ASD due to their ability to modulate gene expression, potentially influencing complex networks involved in neuronal function. However, their broad